# An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

> **NCT02488330** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Onartuzumab
- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02488330
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-27
- **Primary completion:** 2018-06-29
- **Final completion:** 2018-06-29
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02488330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02488330, "An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02488330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*